Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer

L. M. Itri, Richard J. Gralla, D. P. Kelsen, R. A. Chapman, E. S. Casper, D. W. Braun, J. E. Howard, R. Golbey, R. T. Heelan

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Fifty-four patients with advanced squamous, large-cell or adeno-carcinoma of the lung were treated with a three drug regimen of high-dose cisplatin, vindesine and a four-day bleomycin infusion (CVB). All patients had measurable disease; none had previously received chemotherapy. Of 52 patients evaluable for response, 20 (38%) had complete or partial remissions. The median duration of remission was 8 months (range, 6 1/2 -19+ months), with eight patients continuing in remission. The median duration of survival for responding patients was 16 months versus five months for nonresponding patients (P>0.001). Toxicity included mild to moderate myelosuppression, peripheral neuropathy, and nephrotoxicity, and was generally manageable. The addition of a four-day bleomycin infusion did not appear to offer a significant advantage over the combination of high-dose cisplatin and vindesine in the treatment of NSCLC. The response rate and survival duration produced by the CVB protocol were similar to those reported for the two-drug combination of vindesine and high-dose cisplatin.

Original languageEnglish (US)
Pages (from-to)1050-1055
Number of pages6
JournalCancer
Volume51
Issue number6
DOIs
StatePublished - 1983
Externally publishedYes

Fingerprint

Vindesine
Bleomycin
Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Cisplatin
Peripheral Nervous System Diseases
Drug Combinations
Survival Rate
Epithelial Cells
Carcinoma
Drug Therapy
Lung
Survival
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Itri, L. M., Gralla, R. J., Kelsen, D. P., Chapman, R. A., Casper, E. S., Braun, D. W., ... Heelan, R. T. (1983). Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer. Cancer, 51(6), 1050-1055. https://doi.org/10.1002/1097-0142(19830315)51:6<1050::AID-CNCR2820510613>3.0.CO;2-F

Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer. / Itri, L. M.; Gralla, Richard J.; Kelsen, D. P.; Chapman, R. A.; Casper, E. S.; Braun, D. W.; Howard, J. E.; Golbey, R.; Heelan, R. T.

In: Cancer, Vol. 51, No. 6, 1983, p. 1050-1055.

Research output: Contribution to journalArticle

Itri, LM, Gralla, RJ, Kelsen, DP, Chapman, RA, Casper, ES, Braun, DW, Howard, JE, Golbey, R & Heelan, RT 1983, 'Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer', Cancer, vol. 51, no. 6, pp. 1050-1055. https://doi.org/10.1002/1097-0142(19830315)51:6<1050::AID-CNCR2820510613>3.0.CO;2-F
Itri, L. M. ; Gralla, Richard J. ; Kelsen, D. P. ; Chapman, R. A. ; Casper, E. S. ; Braun, D. W. ; Howard, J. E. ; Golbey, R. ; Heelan, R. T. / Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer. In: Cancer. 1983 ; Vol. 51, No. 6. pp. 1050-1055.
@article{69b4ed83beda4f4781168d03a4436672,
title = "Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer",
abstract = "Fifty-four patients with advanced squamous, large-cell or adeno-carcinoma of the lung were treated with a three drug regimen of high-dose cisplatin, vindesine and a four-day bleomycin infusion (CVB). All patients had measurable disease; none had previously received chemotherapy. Of 52 patients evaluable for response, 20 (38{\%}) had complete or partial remissions. The median duration of remission was 8 months (range, 6 1/2 -19+ months), with eight patients continuing in remission. The median duration of survival for responding patients was 16 months versus five months for nonresponding patients (P>0.001). Toxicity included mild to moderate myelosuppression, peripheral neuropathy, and nephrotoxicity, and was generally manageable. The addition of a four-day bleomycin infusion did not appear to offer a significant advantage over the combination of high-dose cisplatin and vindesine in the treatment of NSCLC. The response rate and survival duration produced by the CVB protocol were similar to those reported for the two-drug combination of vindesine and high-dose cisplatin.",
author = "Itri, {L. M.} and Gralla, {Richard J.} and Kelsen, {D. P.} and Chapman, {R. A.} and Casper, {E. S.} and Braun, {D. W.} and Howard, {J. E.} and R. Golbey and Heelan, {R. T.}",
year = "1983",
doi = "10.1002/1097-0142(19830315)51:6<1050::AID-CNCR2820510613>3.0.CO;2-F",
language = "English (US)",
volume = "51",
pages = "1050--1055",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Cisplatin, vindesine and bleomycin (CVB) combination chemotherapy of advanced non-small cell lung cancer

AU - Itri, L. M.

AU - Gralla, Richard J.

AU - Kelsen, D. P.

AU - Chapman, R. A.

AU - Casper, E. S.

AU - Braun, D. W.

AU - Howard, J. E.

AU - Golbey, R.

AU - Heelan, R. T.

PY - 1983

Y1 - 1983

N2 - Fifty-four patients with advanced squamous, large-cell or adeno-carcinoma of the lung were treated with a three drug regimen of high-dose cisplatin, vindesine and a four-day bleomycin infusion (CVB). All patients had measurable disease; none had previously received chemotherapy. Of 52 patients evaluable for response, 20 (38%) had complete or partial remissions. The median duration of remission was 8 months (range, 6 1/2 -19+ months), with eight patients continuing in remission. The median duration of survival for responding patients was 16 months versus five months for nonresponding patients (P>0.001). Toxicity included mild to moderate myelosuppression, peripheral neuropathy, and nephrotoxicity, and was generally manageable. The addition of a four-day bleomycin infusion did not appear to offer a significant advantage over the combination of high-dose cisplatin and vindesine in the treatment of NSCLC. The response rate and survival duration produced by the CVB protocol were similar to those reported for the two-drug combination of vindesine and high-dose cisplatin.

AB - Fifty-four patients with advanced squamous, large-cell or adeno-carcinoma of the lung were treated with a three drug regimen of high-dose cisplatin, vindesine and a four-day bleomycin infusion (CVB). All patients had measurable disease; none had previously received chemotherapy. Of 52 patients evaluable for response, 20 (38%) had complete or partial remissions. The median duration of remission was 8 months (range, 6 1/2 -19+ months), with eight patients continuing in remission. The median duration of survival for responding patients was 16 months versus five months for nonresponding patients (P>0.001). Toxicity included mild to moderate myelosuppression, peripheral neuropathy, and nephrotoxicity, and was generally manageable. The addition of a four-day bleomycin infusion did not appear to offer a significant advantage over the combination of high-dose cisplatin and vindesine in the treatment of NSCLC. The response rate and survival duration produced by the CVB protocol were similar to those reported for the two-drug combination of vindesine and high-dose cisplatin.

UR - http://www.scopus.com/inward/record.url?scp=0020671917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020671917&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19830315)51:6<1050::AID-CNCR2820510613>3.0.CO;2-F

DO - 10.1002/1097-0142(19830315)51:6<1050::AID-CNCR2820510613>3.0.CO;2-F

M3 - Article

C2 - 6185210

AN - SCOPUS:0020671917

VL - 51

SP - 1050

EP - 1055

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -